« Back to report listing

OVERVIEW

Cost:$3000

PUBLICATION DATE:November 2010

THERAPEUTIC CLASS:Oncology

Number of Pages:118

super report icon

US Breast Cancer

Competitive Market Analysis and Forecast 2010-2013

REPORT SUMMARY

This PharmaPeek report focuses on the US breast cancer market and consists of information pertaining to the key drivers and challenges influencing the ever-changing market. Current and future treatments explored are chemotherapy and to a greater extent, hormone therapy, as well as targeted therapy. You will also find some information on current and future competitors in this rapidly changing space.


EXECUTIVE SUMMARY

About 1 in 8 women in the United States (12%) will develop invasive breast cancer, for which there is no cure, over the course of her lifetime. Death rates are higher than those for any other cancer, besides lung cancer. About 70-80% of breast cancers occur in women who have no family history of breast cancer. These two factors contribute to breast cancer research being among the most dynamic, as well as the most funded.

There is a genetic aspect to the risk of breast cancer, which is also an area of continuing interest. A woman's risk of developing breast cancer approximately doubles if she has a first-degree relative who has been diagnosed with breast cancer. About 5-10% of breast cancers can be linked to gene mutations (abnormal changes) inherited from one's mother or father, of which BRCA1 and BRCA2 gene mutations are the most common.

Breast cancer treatment is specific to the type and stage of breast cancer and can entail any combination of the following: surgery, radiation, chemotherapy, hormone therapy and targeted therapy. Breast cancer patients are also treated based on hormone receptor status, as well as HER2- (human epidermal growth factor receptor 2) status.

This article will discuss the US breast cancer market, consisting of the key drivers and challenges influencing the market. The current competitors in the market, as well as the future competitors will be analyzed as well. Current and future treatments explored are chemotherapy and to a greater extent, hormone therapy, as well as targeted therapy.

Currently, targeted therapy focuses on HER2 status, in the case of trastuzumab and lapatinib, however, compounds are needed to overcome trastuzumab resistance. Further, bevacizumab focuses on VEGF, but there are a plethora of targets in the signal-transduction pathway important in the pathogenesis of breast cancer involving proliferation, angiogenesis, and differentiation of neoplasms. New biomarkers of breast cancer are being investigated to determine if these investigational therapies may have more utility in certain patients. All of the factors described here contribute to the ever changing breast cancer market.


TABLE OF CONTENTS

  • Chapter 1: Introduction to Breast Cancer
    • Understanding Breast Cancer
  • Chapter 2: Breast Cancer Industry Activity Overview
    • Epidemiology-Statistics
    • Risk Factors
    • Lobular Carcinoma in Situ (LCIS) and Breast Cancer Risk
    • Diagnosis
    • Staging
    • How to Determine Treatment
    • Forms of Treatment
    • Competitors
  • Chapter 3: Breast Cancer Market Analysis
    • Key Drivers for the Breast Cancer Market
    • Key Challenges for the Breast Cancer Market
  • Chapter 4: Individual Competitor Overview
    • Chemotherapy
    • Hormone Therapy
    • Targeted Therapy
  • Chapter 5: Pipeline
    • Late-Stage (phase 3)
    • Mid/Early Stage (phase 2)
    • Very Early phase (phase 1 or preclinical)
    • Personalized Medicine
  • Chapter 6: Breast Cancer Summary

COMPANIES DISCUSSED

  • AstraZeneca
  • Novartis
  • Pfizer
  • TAP
  • Strativa
  • GTx
  • Eli Lilly
  • Genentech
  • GSK
  • Roche
  • BMS
  • Aventis
  • Pharmacia & UpJohn
  • Sicor/Teva
  • GlaxoWellcome
  • ImClone
  • SanofiAventis
  • Amgen
  • Abbott
  • Aveo
  • PTC
  • Chiron
  • Array Biopharma
  • Fresenius Biotech
  • Boehringer Ingelheim
  • Biogen Idec
  • OSI
  • Johnson&Johnson
  • Schering Plough
  • Bayer
  • Onyx
  • Celgene
  • Merck
  • Syndax
  • Ariad
  • Keryx
  • Kosan
  • Elelixis
  • ArQule
  • MethylGene
  • Plexxikon
  • Ardea Biosciences
  • MGI
  • Xelexis

DRUGS DISCUSSED

  • Tamoxifen
  • Nolvadex
  • Anastrozole
  • Arimidex
  • Letrozole
  • Femara
  • Exemestane
  • Aromasin
  • Goserelin
  • Zoladex
  • Lupron
  • Leuprolide
  • Fulvesterant
  • Faslodex
  • Megace
  • Megestrol acetate
  • Fareston
  • Toremifene
  • Evsita
  • Raloxifene
  • Trastuzumab
  • Herceptin
  • Tykerb
  • Lapatinib
  • Bevacizumab
  • Avastin
  • Capecitabine
  • Xeloda
  • Paraplatin
  • Carboplatin
  • Cisplatin
  • Platinol
  • Cyclophosphamide
  • Cytoxan
  • CTX
  • Clafen
  • Neosar
  • Taxotere
  • Docetaxel
  • Doxorubicin
  • Adriamycin
  • Doxil
  • Rubex
  • Ellence
  • Epirubicin
  • 5-FU
  • Adrucil
  • Effudex
  • Fluoroplex
  • Gemzar
  • Gemcitabine
  • Ixabepilone
  • Ixempra
  • Liposomal Doxorubicin
  • Caelyx
  • Doxil
  • Evacet
  • Methotrexate
  • Paclitaxel
  • Matrex
  • Rheumatrex
  • Taxol
  • Abraxane
  • Vinorelbine
  • Navelbine
  • Sutent
  • Votrient
  • IMC-1121B
  • Neratinib
  • Pertuzumab
  • Afinitor
  • BSI-102
  • Erbitux
  • Vectibix
  • Gefitinib
  • AZD6474
  • Axitinib
  • AZD2171
  • Linifanib
  • AV-951
  • PTC299
  • CHIR-258
  • ARRY334543
  • Ertumaxomab
  • BIBW2992
  • AMG479
  • CP-751
  • 871
  • IMC-A12
  • R1507
  • BIIB022
  • OSI906
  • Tipifarnib
  • Lonafarnib
  • Nexavar
  • Vidaza
  • Istodax
  • Zolinza
  • Panobinostat
  • SNDX275
  • Deforolimus
  • Torisel
  • AMG386
  • AZD0530
  • Sprycel
  • Triple-Negative
  • Perifisone
  • Tanespimycin
  • Alvespimycin
  • KU-0059436
  • AMG102
  • OA5D5
  • BGT226
  • BEX235
  • XL765
  • XL147
  • XL880
  • ARQ197
  • PF02341066
  • JNJ388
  • MGCD265
  • BMS214662
  • RAF265
  • XL281
  • PLX4032
  • AZD6244
  • RDEA119
  • XL518
  • Dacogen
  • XL999
  • GSK690693
  • BMS599626
  • BMS690514
  • PF00299804
  • XL647